RU2223969C2 - Способы облегчения нейропатической боли с применением пептидов, являющихся производными просапозина - Google Patents

Способы облегчения нейропатической боли с применением пептидов, являющихся производными просапозина Download PDF

Info

Publication number
RU2223969C2
RU2223969C2 RU98118091/04A RU98118091A RU2223969C2 RU 2223969 C2 RU2223969 C2 RU 2223969C2 RU 98118091/04 A RU98118091/04 A RU 98118091/04A RU 98118091 A RU98118091 A RU 98118091A RU 2223969 C2 RU2223969 C2 RU 2223969C2
Authority
RU
Russia
Prior art keywords
seq
prosaposin
peptide
neuropathic pain
active fragment
Prior art date
Application number
RU98118091/04A
Other languages
English (en)
Russian (ru)
Other versions
RU98118091A (ru
Inventor
Джон С. О'БРАЙЕН (US)
Джон С. О'Брайен
Original Assignee
Риджентс оф Дзе Юниверсити оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Риджентс оф Дзе Юниверсити оф Калифорния filed Critical Риджентс оф Дзе Юниверсити оф Калифорния
Publication of RU98118091A publication Critical patent/RU98118091A/ru
Application granted granted Critical
Publication of RU2223969C2 publication Critical patent/RU2223969C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU98118091/04A 1996-03-05 1997-03-05 Способы облегчения нейропатической боли с применением пептидов, являющихся производными просапозина RU2223969C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/611,307 1996-03-05
US08/611,307 US6271196B1 (en) 1996-03-05 1996-03-05 Methods of alleviating neuropathic pain using prosaposin-derived peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2003131695/14A Division RU2266129C2 (ru) 1996-03-05 1997-03-05 Способ воздействия на нейродегенеративное нарушение или нарушение миелинизации

Publications (2)

Publication Number Publication Date
RU98118091A RU98118091A (ru) 2000-10-20
RU2223969C2 true RU2223969C2 (ru) 2004-02-20

Family

ID=24448513

Family Applications (2)

Application Number Title Priority Date Filing Date
RU98118091/04A RU2223969C2 (ru) 1996-03-05 1997-03-05 Способы облегчения нейропатической боли с применением пептидов, являющихся производными просапозина
RU2003131695/14A RU2266129C2 (ru) 1996-03-05 1997-03-05 Способ воздействия на нейродегенеративное нарушение или нарушение миелинизации

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2003131695/14A RU2266129C2 (ru) 1996-03-05 1997-03-05 Способ воздействия на нейродегенеративное нарушение или нарушение миелинизации

Country Status (16)

Country Link
US (2) US6271196B1 (enExample)
EP (1) EP0929569B1 (enExample)
JP (1) JP4138006B2 (enExample)
KR (1) KR100507715B1 (enExample)
AT (1) ATE340187T1 (enExample)
AU (1) AU734566B2 (enExample)
CA (1) CA2248139C (enExample)
CZ (1) CZ297384B6 (enExample)
DE (1) DE69736712T2 (enExample)
IL (1) IL126082A0 (enExample)
NO (1) NO984093L (enExample)
NZ (1) NZ331757A (enExample)
PL (1) PL187917B1 (enExample)
RU (2) RU2223969C2 (enExample)
SK (1) SK122898A3 (enExample)
WO (1) WO1997032895A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) * 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US6849602B1 (en) * 1996-03-05 2005-02-01 The Regents Of The University Of California Compositions for alleviating neuropathic pain with prosaposin receptor agonists
EP0979238A4 (en) * 1997-03-05 2000-08-23 Univ California METHOD FOR HEALING NEUROPATHIC PAIN
AU4267297A (en) * 1997-09-11 1998-09-22 Regents Of The University Of California, The Method of alleviating neuropathic pain
WO1998042746A2 (en) * 1997-03-24 1998-10-01 Myelos Corporation Synthetic saposin c-derived neurotrophic peptides
AU9774698A (en) * 1997-09-09 1999-03-29 Regents Of The University Of California, The Inhibition of apoptotis using prosaposin receptor agonists
US6458357B1 (en) * 1997-09-09 2002-10-01 Myelos Corporation Retro-inverso neurotrophic and analgesic peptides
PL204359B1 (pl) * 1998-08-28 2010-01-29 Myelos Corp Cykliczne peptydy, zawierająca je kompozycja farmaceutyczna i ich zastosowania
US20020028783A1 (en) * 1999-09-09 2002-03-07 O'brien John S. Method of stimulating prosaposin receptor activity
USRE45976E1 (en) * 1999-02-24 2016-04-19 Tact Ip, Llc Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally
WO2000058359A1 (en) * 1999-03-30 2000-10-05 Myelos Corporation Retro-inverso prosaposin-derived peptides and use thereof
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7410941B1 (en) 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
WO2000077033A1 (en) * 1999-06-16 2000-12-21 Myelos Corporation Retro-inverso peptides derived from interleukin-6
EP1183266A4 (en) * 1999-06-16 2002-10-23 Myelos Corp INVERTED RETRO PEPTIDES DERIVED FROM LEUKEMIA INHBITION FACTOR
US7135461B1 (en) 2000-06-16 2006-11-14 Myelos Corporation Retro-inverso peptides derived from interleukin-6
US7109168B1 (en) 2000-06-16 2006-09-19 Myelos Corporation Retro-inverso peptides derived from leukemia inhibitory factor
CA2376394A1 (en) * 1999-06-16 2000-12-21 David E. Wright Retro-inverso peptides derived from interleukin-3
US20040170955A1 (en) * 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US7452964B2 (en) * 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US20050074747A1 (en) * 2000-09-08 2005-04-07 Wadih Arap Biopanning and rapid analysis of selective interactive ligands (brasil)
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20060287240A1 (en) * 2001-03-09 2006-12-21 O'brien John S Method of stimulating prosaposin receptor activity
EP1418932A4 (en) * 2001-07-18 2006-03-15 Univ Texas ANTI-ANGIOGENIC STATE IN MOUSE AND HUMAN BEINGS SUFFERING FROM CELL DEGENERATION OF THE RETINAL PHOTORECEPTOR
US20040048243A1 (en) * 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US8507445B2 (en) * 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US20040096089A1 (en) * 2002-08-16 2004-05-20 David Borsook Non-invasive functional imaging of peripheral nervous system activation in humans and animals
US7166691B2 (en) * 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
US20060275274A1 (en) * 2003-03-26 2006-12-07 Daria Onichtchouk Use of saposin-related proteins for preventing and treating obesity, diabetes and/or metabolic syndrome
BRPI0409523A (pt) * 2003-03-28 2006-04-18 Acadia Pharm Inc método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
US7834147B2 (en) * 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
CN100366286C (zh) * 2003-04-28 2008-02-06 常州南云科技有限公司 Saposin C-DOPS:一种抗癌新药
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
EP1736481A1 (en) * 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
RU2317829C2 (ru) * 2005-10-05 2008-02-27 Федеральное государственное учреждение науки "Екатеринбургский медицинский научный центр профилактики и охраны здоровья рабочих промпредприятий" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ лечения мононевропатий верхних конечностей
US7964585B2 (en) * 2006-03-14 2011-06-21 Case Western Reserve University Composition and method of treating peripheral neuropathy
RU2345786C2 (ru) * 2007-02-27 2009-02-10 Андрей Евгеньевич Кульчиков Способ лечения непрерывно-прогредиентных дегенеративных и демиелинизирующих заболеваний
NZ621196A (en) 2008-01-22 2015-08-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
RU2561582C2 (ru) * 2010-11-19 2015-08-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Инъекционная лекарственная форма олигопептидного препарата для лечения рассеянного склероза и способ ее получения
JP5971729B2 (ja) * 2011-02-23 2016-08-17 北海道公立大学法人 札幌医科大学 疼痛を治療、改善、または予防するための組成物
RU2669692C1 (ru) * 2017-08-14 2018-10-15 Павел Андреевич Канаев Способ получения комплекса биологически активных пептидов обладающих нейротропной активностью
EP3768246B1 (en) 2018-03-23 2021-08-25 Bexion Pharmaceuticals, Inc. Saposin c pharmaceutical compositions and their use in treating cancer
RU2020131598A (ru) 2018-03-29 2022-04-29 Лэйтерал Ип Пти Лтд Циклические пептиды и их применение
KR20230130693A (ko) * 2021-01-09 2023-09-12 벡션 파마슈티컬스 인크. 신경병증 및 신경병증 증상을 감소시키고 암을 치료하는방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169764A (en) * 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
RU2007417C1 (ru) * 1991-06-21 1994-02-15 Российский государственный медицинский университет Способ получения плацентарного протеина
WO1995013823A1 (en) * 1993-11-15 1995-05-26 Celtrix Pharmaceuticals, Inc. Method of treating neurological disorders
RU2037498C1 (ru) * 1989-04-28 1995-06-19 Пфайзер Инк. Способ получения полипептидов
US5534495A (en) * 1993-05-25 1996-07-09 Advanced Peptides And Biotechnology Sciences Treatment of non-HIV neuropathic pain syndromes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0246753B1 (en) 1986-04-22 1994-07-13 The Salk Institute For Biological Studies Fibroblast growth factor antagonists
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
EP0979238A4 (en) * 1997-03-05 2000-08-23 Univ California METHOD FOR HEALING NEUROPATHIC PAIN
WO1998042746A2 (en) * 1997-03-24 1998-10-01 Myelos Corporation Synthetic saposin c-derived neurotrophic peptides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2037498C1 (ru) * 1989-04-28 1995-06-19 Пфайзер Инк. Способ получения полипептидов
US5169764A (en) * 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
RU2007417C1 (ru) * 1991-06-21 1994-02-15 Российский государственный медицинский университет Способ получения плацентарного протеина
US5534495A (en) * 1993-05-25 1996-07-09 Advanced Peptides And Biotechnology Sciences Treatment of non-HIV neuropathic pain syndromes
WO1995013823A1 (en) * 1993-11-15 1995-05-26 Celtrix Pharmaceuticals, Inc. Method of treating neurological disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
O'Brien JS., FASEB J., 1995, May, 9(8), p. 681-685. O'Brien JS., Proc. Natl. Acad. Sci. USA, 1994, Sep. 27, 91(20), p. 9593-9596. *

Also Published As

Publication number Publication date
WO1997032895A1 (en) 1997-09-12
ATE340187T1 (de) 2006-10-15
RU2003131695A (ru) 2005-04-10
KR19990087686A (ko) 1999-12-27
EP0929569A4 (en) 2000-08-23
US6268347B1 (en) 2001-07-31
JP2000506853A (ja) 2000-06-06
AU2328697A (en) 1997-09-22
NZ331757A (en) 1999-10-28
DE69736712D1 (de) 2006-11-02
CZ297384B6 (cs) 2006-11-15
EP0929569B1 (en) 2006-09-20
KR100507715B1 (ko) 2006-05-26
EP0929569A1 (en) 1999-07-21
SK122898A3 (en) 2000-02-14
CZ283998A3 (cs) 1999-05-12
JP4138006B2 (ja) 2008-08-20
DE69736712T2 (de) 2007-09-13
US6271196B1 (en) 2001-08-07
RU2266129C2 (ru) 2005-12-20
CA2248139C (en) 2004-05-18
CA2248139A1 (en) 1997-09-12
IL126082A0 (en) 1999-05-09
PL187917B1 (pl) 2004-11-30
NO984093D0 (no) 1998-09-04
AU734566B2 (en) 2001-06-14
PL328701A1 (en) 1999-02-15
NO984093L (no) 1998-11-04

Similar Documents

Publication Publication Date Title
RU2223969C2 (ru) Способы облегчения нейропатической боли с применением пептидов, являющихся производными просапозина
RU98118091A (ru) Способы облегчения нейропатической боли с применением пептидов, являющихся производными просапозина
Chen et al. BDNF enhances retinal ganglion cell survival in cats with optic nerve damage
Sauer et al. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion.
Tagami et al. Axonal regeneration induced by repetitive electrical stimulation of crushed optic nerve in adult rats
HUP0103265A2 (hu) Proszapozineredetű ciklikus peptidek, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
EP0510186A4 (en) Therapeutic uses of melanin
BR112020020346A2 (pt) Neurotoxinas para uso na inibição de cgrp
Blair et al. Effect of glatiramer acetate on primary and secondary degeneration of retinal ganglion cells in the rat
EP3066116B1 (en) Treatment of damaged nerve with pten inhibitor
Barbaro Studies of PAG/PVG stimulation for pain relief in humans
Hefti et al. Protective effects of nerve growth factor and brain-derived neurotrophic factor on basal forebrain cholinergic neurons in adult rats with partial fimbrial transections
DE60101977T2 (de) Selenocosmia huwena Toxin und Verwendung als Analgetikum
AU2804192A (en) Treatment of neurological conditions by an interleukin-1 inhibiting compound
US5534495A (en) Treatment of non-HIV neuropathic pain syndromes
US6268340B1 (en) In vivo regeneration of oligodendrocytes by bolus injection of NGFβ
WO1996028180A9 (en) Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes
US5830857A (en) Method of treating epilepsy
CN112076193B (zh) 甲氧喹酸在制备用于治疗和/或预防以t-型钙通道为治疗靶点的疾病的药物中的应用
US20070148159A1 (en) Use of crotoxin as an analgesic - CIP
AU754982B2 (en) Compositions for promoting nerve regeneration
CA2284105A1 (en) Synthetic saposin c-derived neurotrophic peptides
CN101555284B (zh) 截短型人睫状神经营养因子活性片段及其融合蛋白
JP2000514038A (ja) Ｉｇｆ−ｉまたはｉｇｆ−ｉｉの投与による中枢神経系における変化をもたらす方法
SAUER et al. 6-hydroxydopamine lesion

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20080306